Tumors Metastatic to Brain Clinical Trial
Official title:
Dose Escalation for Larger Brain Metastases: Phase I/II Study
This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.
PRIMARY OBJECTIVES: I. To determine the incidence of acute and long-term toxicities with increasing dose of stereotactic radiosurgery (SRS). (Phase I) II. To determine if local control may be improved with increasing doses of SRS. (Phase II) SECONDARY OBJECTIVES: I. To determine the risk of acute and long-term toxicity with increasing dose of SRS. (Phase II) II. To determine if there is increased neurocognitive toxicity with increased dose of SRS. III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine if quality of life is affected more by tumor recurrence versus radiation necrosis. This includes assessment of progression free survival, overall survival, local failure, and number of patients who receive bevacizumab, laser interstitial thermal therapy, or surgery for presumed radiation necrosis. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. Patients undergo SRS guided by computer tomography (CT) and magnetic resonance imaging (MRI). After completion of treatment, patients are followed up at 1-2, 3, 6, 9, and 12 months, every 3 months for 2 years, and then every 4 months thereafter. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02107755 -
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
Completed |
NCT01703507 -
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
|
Phase 1 | |
Completed |
NCT00033254 -
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
|
Phase 3 | |
Active, not recruiting |
NCT01706432 -
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
|
||
Recruiting |
NCT01891318 -
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
|
Phase 1/Phase 2 | |
Completed |
NCT01276210 -
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
|
Phase 1 | |
Completed |
NCT01234740 -
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
|
Phase 1 | |
Completed |
NCT02312622 -
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT00937482 -
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT02269111 -
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
|
N/A | |
Withdrawn |
NCT02277561 -
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
|
N/A | |
Completed |
NCT00992602 -
Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT02145910 -
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
|
Phase 1 |